European regulators have begun an investigation into a possible risk of cancer in patients taking angiotensin II receptor inhibitors for …
Boehringer Ingelheim has given a robust rebuttal to a Lancet report implicating its hypertension drug Micardis (telmisartan) in scares about …
Trio become latest Symbiosis commercial additions
UK immunoglobulin supply faces growing pressure, report warns
How will biomarker-led diagnostics reshape respiratory medicine?

